AFT on track to refinance CRG term loan facility

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 26 February 2020

AFT on track to refinance CRG term loan facility
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces that its six -year term loan
facility from CRG maturing on 31 March 2020 is on track to be refinanced with a three-
year term loan from a local commercial bank.
Committed term sheets have been entered into and the parties expect the
agreements to be finalised shortly.
AFT expects its new facilities will result in total finance cost savings of more than $2
million per year over the term of the loan, which is due to commence at the start of
the new financial year.
AFT Pharmaceuticals CFO Malcolm Tubby said: “We are pleased to have concluded
these term sheets and look forward to finalising the loan documentation. The
refinancing has no impact on AFT’s outlook for the current financial year and we retain
our guidance for an FY20 operating profit of between $18.8m and $21.8m.”
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We thank CRG for
its invaluable support over this transformative period in AFT’s history which has set the
company up for future growth in both local and International markets.”
For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO

For more information:
Investors Media
Malcolm Tubby Richard Inder
CFO The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232


About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over-the-counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com
.